巨细胞病毒免疫监测——我们从这里走向何方？ - Suppr | 超能文献

CMV immune monitoring-Where do we go from here?

作者信息

Kumar Deepali, Humar Atul

机构信息

Transplant Infectious Diseases, Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.

出版信息

Am J Transplant. 2020 Aug;20(8):1961-1962. doi: 10.1111/ajt.15875. Epub 2020 Apr 15.

DOI:10.1111/ajt.15875

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

CMV immune monitoring-Where do we go from here?巨细胞病毒免疫监测——我们从这里走向何方？

Am J Transplant. 2020 Aug;20(8):1961-1962. doi: 10.1111/ajt.15875. Epub 2020 Apr 15.

2

Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.采用商品化酶联免疫吸附法（ELISA）检测干扰素-γ释放试验监测抗胸腺细胞球蛋白治疗的肾移植受者巨细胞病毒特异性细胞免疫。

Am J Transplant. 2020 Aug;20(8):2070-2080. doi: 10.1111/ajt.15793. Epub 2020 Feb 21.

3

CMV cell-mediated immunity assays: Focus on CD4 cells.巨细胞病毒细胞介导免疫测定：聚焦于CD4细胞。

Am J Transplant. 2020 Aug;20(8):2285-2286. doi: 10.1111/ajt.15866. Epub 2020 Apr 5.

4

CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.CMV 特异性细胞介导免疫在 3 个月预防停药时可区分 D+/R+ 肾移植患者，无论诱导治疗类型如何，这些患者都有发生迟发性 CMV 感染的风险。

Transplantation. 2018 Nov;102(11):e472-e480. doi: 10.1097/TP.0000000000002421.

5

Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient.采用过继性T细胞免疫疗法治疗肾移植受者的耐更昔洛韦巨细胞病毒病。

Am J Transplant. 2015 Mar;15(3):827-32. doi: 10.1111/ajt.13023. Epub 2015 Feb 3.

6

Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.评估适合的靶抗原和免疫测定法，用于对巨细胞病毒和EB病毒特异性T细胞进行高精度免疫监测，这些细胞是免疫治疗方法中感兴趣的靶标。

J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28.

7

Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.更昔洛韦转换治疗后缬更昔洛韦在巨细胞病毒高风险腹部实体器官移植受者可能会促进巨细胞病毒特异性细胞介导的免疫反应。

Transpl Infect Dis. 2022 Feb;24(1):e13766. doi: 10.1111/tid.13766. Epub 2021 Dec 7.

8

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. preemptive 与序贯预防性-抢先治疗方案在肾移植中治疗巨细胞病毒：治疗失败和抗病毒耐药的比较。

Transplantation. 2010 Feb 15;89(3):320-6. doi: 10.1097/TP.0b013e3181bc0301.

9

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.在接受抗淋巴细胞抗体治疗的巨细胞病毒血清学阳性肾移植和肝移植受者中，先进行静脉注射更昔洛韦抢先治疗后，口服阿昔洛韦或更昔洛韦预防巨细胞病毒疾病的疗效。

Transplantation. 1998 Dec 27;66(12):1780-6. doi: 10.1097/00007890-199812270-00036.

10

Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.巨细胞病毒定量干扰素检测在肾移植受者管理中的临床应用

Transplant Proc. 2016 Jun;48(5):1650-3. doi: 10.1016/j.transproceed.2016.01.046.

引用本文的文献

1

Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.巨细胞病毒细胞介导免疫测定在实体器官移植中的应用。

J Clin Microbiol. 2022 Aug 17;60(8):e0171621. doi: 10.1128/jcm.01716-21. Epub 2022 May 11.